MarketPulse

Phase III trial

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Advances Cancer Pipeline with Phase III HMPL-760 Trial Launch

HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory lymphoma in China, enrolling 240 patients following positive Phase II results.
HCMclinical developmentoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Ultragenyx Faces Class Action Over Setrusumab Trial Data Misrepresentation

Class action lawsuit filed against Ultragenyx Pharmaceutical alleging false statements about setrusumab efficacy for Osteogenesis Imperfecta treatment based on flawed trial comparisons.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Ultragenyx Hit With Class Action Over Setrusumab Trial Data Misrepresentations

Class action filed against Ultragenyx ($RARE) alleging misrepresented setrusumab trial data. Investors purchasing August 2023-December 2025 may recover damages.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Ultragenyx Over Setrusumab Trial Disclosures

Ultragenyx faces class action lawsuit for allegedly misleading investors about setrusumab efficacy and failing to disclose Phase III trial risks adequately.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Ultragenyx Over Setrusumab Trial Disclosures

Ultragenyx Pharmaceutical faces class action lawsuit for allegedly making false statements about setrusumab drug efficacy and safety, affecting investors who bought securities between August 2023 and December 2025.
RAREsecurities fraudclass action lawsuit